预测和克服癌症治疗中对CDK9抑制剂的耐药性
Chen Hu1,2, Lijuan Shen1,3, Fengming Zou1,2
1Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China.
在CDK9 (循环素依赖激酶9) 中发生的新突变导致对癌症药物的耐药性. 研究人员确定了这种突变,并开发了一种新化合物来克服这种抵抗力,为未来的癌症治疗提供了希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 循环素依赖性激酶9 (CDK9) 对于癌细胞存活至关重要,是抗癌药物的标.
- 关于对CDK9抑制剂的耐药性机制的知识有限.
研究的目的:
- 在急性髓性白血病 (AML) 中调查对选择性CDK9抑制剂的获得药物耐药性.
- 确定 CDK9 抑制剂耐药性背后的分子机制.
- 发现新的治疗策略来克服CDK9抑制剂耐药性.
主要方法:
- 通过使用CDK9抑制剂 (BAY1251152) 建立了耐药AML细胞系.
- 利用基因组测序和CRISPR/Cas9基因编辑来识别和验证CDK9 L156F突变.
- 评估突变对抑制剂结合,蛋白质稳定性和催化活性的影响.
- 对新型化合物进行选,这些化合物对野生类型和突变的CDK9.9都有效.
主要成果:
- 鉴定了一种新的CDK9激酶域突变,L156F,对ATP竞争性抑制剂和PROTAC降解剂产生抗性.
- 这种L156F突变会导致固体阻碍,损害抑制剂结合,改变CDK9蛋白的稳定性和活性.
- 发现了一种新型化合物IHMT-CDK9-36,具有强大的抑制活性,对抗野生类型和L156F突变CDK9.
结论:
- 报告了一种由CDK9 L156F突变调解的药物耐药性的新机制.
- 证明L156F突变会对各种CDK9抑制剂产生抗性.
- 提出IHMT-CDK9-36作为一个有前途的化学支架,用于开发对抗耐药突变有效的下一代CDK9抑制剂.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
相关概念视频
Inhibition of Cdk Activity
Treatment Resistant Cancers
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
